Here's why the Immutep (ASX:IMM) share price is frozen

The company's shares will remain in a trading halt until Monday or pending a further update.

For the second day in a row, the Immutep Ltd (ASX: IMM) share price will be frozen at market open.

Yesterday, Immutep entered a trading halt until Monday's open, or until such time as the company releases further news regarding a capital raise, whichever comes first.

When Immutep shares closed on Wednesday ­– their latest active session ­– they were swapping hands for 62 cents apiece.

Let's take a look at what we know so far of the biotechnology company's capital raise.

a doctor looking up at question marks

Image source: Getty Images

New capital raise

According to Immutep, the capital raise will be an institutional placement. However, the company has not yet stated how much it hopes to raise during the activity.

Additionally, Immutep hasn't yet disclosed why it will be conducting the capital raise.

Market watchers will be keeping an eye on the company today, as further details of its latest placement are likely to be announced before Monday's open.

The last institutional placement completed by Immutep took place in August 2020. Through that placement, the company raised $29.6 million by issuing 123.3 million new shares at 24 cents per share to institutional investors.

Immutep's previous capital raise was used to boost its clinical programs budget.

It mostly went towards the ongoing development of the company's IMP123 – a drug that regulates the immune system. However, a portion of the capital raised went towards Immutep's immunosuppressive agonist drug IMP761, which is still in preclinical stages.

Immutep share price snapshot

2021 has been a good year on the ASX so far for Immutep shares.

The Immutep share price is currently 48% higher than it was at the start of this year. It has also gained 305% since this time last year.

The company has a market capitalisation of around $444 million, with approximately 648 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »